Arcis Biotechnology is a research and development led company with expertise in the development and commercialization of a wide range of fast and convenient sample preparation technologies. Based at Sci-tech Daresbury, where we have fully equipped laboratory facilities, the Group has already developed a number of patented compounds and technologies that have been enthusiastically received in the commercial marketplace via our licensing partners.

Peter Whitehurst - CEO

A Qualified Chartered Accountant by background, Peter thrives on driving business change through an Organisation.
Peter was a key member of the SSL Executive Team that accepted a bid from Reckitt Benckiser for £2.54 billion to acquire SSL in 2010. Peter headed up the Innovation & Technology teams in SSL and a healthy track record of successful product innovations coupled with an exciting pipeline of future products helped ensure a healthy price premium for shareholders. Peter thrives on building high performing teams and giving them the remit, funds and business focus to produce exciting tangible results.

Dr Jan Rogers - CSO

Jan has extensive knowledge of the development and commercialization of innovative medical devices. She has been responsible for the introduction of New Product Development processes which have led to the successful launch of numerous products in both the healthcare and consumer markets – most notably Regent synthetic surgical gloves and the new Aquacel® woundcare  products. Jan held senior R&D positions at London International Group, Regent Medical, Molnlycke Healthcare, Convatec Inc and SSL International before joining Arcis Biotechnology in May 2011. Jan has a PhD in Surface Chemistry from the University of Reading and an MBA specializing in Innovation from the University of Bath.

Dr Jamie Paterson - Chairman

Jamie joined Arcis Biotechnology on April 1st 2016 and has over 25 years’ experience in the pharmaceutical industry. Jamie spent 18 years at Proctor & Gamble, predominantly in the Healthcare Division, in a variety of senior positions, including European Director of Strategic Planning and New Business Development. He has held CEO positions at three healthcare start-ups where he led product development and commercialisation before managing successful exits. Jamie is currently CEO of Relitect Limited which is developing a novel diagnostic technology. Jamie holds a PhD in Biochemistry from Imperial College, University of London.